文献速递小儿麻醉气道管理

新生儿、婴儿和儿童神经肌肉接头发育与神经肌肉阻滞剂:叙述性综述

Development of the neuromuscular junction and neuromuscular blocking agents in neonates, infants and children: A narrative review.
PubMed 文献 · Eur J Anaesthesiol · 2025-09-03

本文为叙述性综述,探讨神经肌肉阻滞剂在新生儿、婴儿和儿童中的药理学特性、临床应用、监测、拮抗及安全性。新生儿和婴儿因肝肾成熟及神经肌肉接头发育的特殊生理,药物代谢、疗效和不良反应与年长儿及成人显著不同,需特定选择、剂量和监测策略,并强调定量监测避免残余阻滞。

要点

  • 新生儿和婴儿神经肌肉阻滞剂代谢、疗效及不良反应与年长儿和成人显著不同。
  • 需根据年龄相关的药代和药效差异选择药物、调整剂量并监测阻滞深度。
  • 推荐使用定量监测技术避免残余神经肌肉阻滞。

核心结论

  • 新生儿和婴儿因肝肾成熟及神经肌肉接头发育差异,神经肌肉阻滞剂的应用需特定方法。
  • 定量监测和新型拮抗剂(如舒更葡糖)有望改善儿科麻醉安全性,但新生儿应用需进一步研究。

研究设计与样本

  • 叙述性综述,未报告系统检索范围或样本量。

主要发现

  • 新生儿和婴儿的神经肌肉阻滞剂代谢、疗效和不良反应与年长儿及成人显著不同。
  • 年龄相关的药代动力学和药效学差异影响阻滞起效、维持和恢复。

临床怎么用

  • 根据年龄相关的药代和药效差异选择神经肌肉阻滞剂、调整剂量并监测。
  • 使用定量监测技术避免残余神经肌肉阻滞。

局限性

  • 新生儿人群应用舒更葡糖等新型拮抗剂需进一步研究。
  • 需制定年龄特异性指南和药理创新以应对新生儿、婴儿和儿童的特殊挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neuromuscular blocking agents (NMBAs) are critical components in paediatric anaesthesia, facilitating intubation, surgical procedures and mechanical ventilation in neonates, infants and children. This narrative review examines the pharmacological properties, clinical applications, monitoring, reversal and safety of NMBAs across paediatric populations. Given the unique physiological characteristics of neonates and infants - including hepatic and renal maturation, and neuromuscular junction development - NMBA metabolism, efficacy and adverse effects in these age groups differ markedly from those in older children and adults. These physiological factors necessitate specific approaches to NMBA selection, dosing and monitoring to ensure effective blockade while minimising risks. Emphasis is placed on understanding how the pharmacokinetics and pharmacodynamics of commonly used NMBAs vary with age, influencing onset, duration and recovery. Additionally, practical strategies for the safe and effective monitoring of neuromuscular blockade using quantitative monitoring techniques are discussed to avoid residual neuromuscular blockade. Recent advances in the reversal of neuromuscular blockade, including the use of sugammadex, offer promising improvements in paediatric anaesthesia safety, though their application in neonatal populations requires further study. Finally, the review discusses current research trends, highlighting the need for age-specific guidelines and pharmacologic innovations that address the challenges unique to NMBA use in neonates, infants, and children.

来源:Eur J Anaesthesiol,查看原文。版权归原作者所有。

引用

  1. Saldien V, Veyckemans F, Hansen TG, et al. Development of the neuromuscular junction and neuromuscular blocking agents in neonates, infants and children: A narrative review. Eur J Anaesthesiol. 2025. PMID: 40905255. doi:10.1097/EJA.0000000000002270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。